Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis

Full Text:


Objective: to assess the predictors and prevalence of adverse drug reactions (ADRs) associated with antiparkinsonian drugs.

Materials and methods. 18 clinical studies and randomized controlled trials were included in the analysis. We combined all registered ADRs for each drug and made direct comparisons with odds ratio (OR) and 95% confidence interval (95% CI) calculation.

Results and discussion. Levodopa/benserazide (LB) had the best safety profile among levodopa drugs. Levodopa/carbidopa (LC) compared with LB was associated with more frequent development of nausea (OR=2.8; 95% CI: 1.51–5.21), aggravation of parkinsonism (OR=4.44; 95% CI: 2.12–9.28) and dizziness (OR=3.32; 95% CI: 1.5–7.33; p=0.002). Piribedil had the lowest number of ADRs among dopamine receptor agonists. Dizziness was more common with pramipexole and ropinirole than with levodopa (OR=1.82; 95% CI: 1.21–2.74 and OR=1.65; 95% CI: 1.11–2.44 respectively). Increased daytime sleepiness and peripheral edema have also been associated with pramipexole. Arterial hypertension was present in 9.6% of patients prescribed with piribedil. Amantadine compared with pramipexole was associated with a higher risk of hallucinations (OR=2.27; 95% CI: 1.24–4.12) and constipation (OR=2.40; 95% CI: 1.14–5.05). Patients prescribed with selegeline had higher odds of dizziness (OR=3.40; 95% CI: 1.76–6.55) and hallucinations (OR=4.30; 95% CI: 1.83–10.09) compared to rasagiline.

Conclusion. Based on the results, we propose a diagram of the relationship between ADRs and their frequency with antiparkinsonian drugs. We hope that the study will find clinical application and allow neurologists to consider the effectiveness and the expected risks of ADRs in the treatment of PD.

About the Authors

A. A. Tappakhov
M.K. Ammosov North-Eastern Federal University
Russian Federation

Aleksey Alekseevich Tappakhov

58, Belinsky St., Yakutsk 677000

T. E. Popova
Yakutsk Science Centre of complex medical problems
Russian Federation

6, Yaroslavskogo St., Build. 3, Yakutsk 677000

A. I. Vasilev
M.K. Ammosov North-Eastern Federal University
Russian Federation

58, Belinsky St., Yakutsk 677000

T. G. Govorova
M.K. Ammosov North-Eastern Federal University
Russian Federation

58, Belinsky St., Yakutsk 677000

Yu. I. Khabarova
Yakutsk Science Centre of complex medical problems
Russian Federation

6, Yaroslavskogo St., Build. 3, Yakutsk 677000

K. A. Timofeeva
M.K. Ammosov North-Eastern Federal University
Russian Federation

58, Belinsky St., Yakutsk 677000

N. A. Schnaider
V.M.Bekhterev National Medical Research Center for Psychiatry and Neurology Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

3, Bekhterev St., Saint-Petersburg 192019,

1, Partisan Zheleznyak St., Krasnoyarsk 660022


1. Levin OS, Artem'ev DV, Bril' EV, et al. Parkinson's disease: modern approaches to diagnosis and treatment. Prakticheskaja medicina = Practical Medicine. 2017;1(102):45-51 (In Russ.).

2. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep;32(9):1264-310. doi: 10.1002/mds.27115

3. Verejutina IA, Zhuravleva EYu, Illarioshkin SN, et al. New treatment options for neuropsychological disorders in patients with early stages of Parkinson's disease. Kremlevskaja medicina. Klinicheskij vestnik = Kremlin Medicine. Clinical Bulletin. 2013;(3):20-4 (In Russ.).

4. Nodel' MR. Sleep disorders in Parkinson's disease. Nevrologija, nejropsihiatrija, psihosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):51-6. doi: 10.14412/2074-2711-2011-135 (In Russ.).

5. Lewitt PA. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1.

6. Titova NV, Katunina EA. Levodopa: the story continues. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2014;(9):93-9 (In Russ.).

7. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2017;16(8):1239-52. doi: 10.2174/1570159x15666170510143821

8. Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020;16(5):403-14. doi: 10.1080/17425255.2020.1750596

9. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24(11):941-68. doi: 10.2165/11537810-000000000-00000

10. Parfenov VA. Early diagnosis and treatment of Alzheimer's disease. Medicinskij sovet = Medical Advice. 2015;(5):28-33 (In Russ.).

11. Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425-39. doi: 10.2174/1871527316666170124165222

12. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: A randomized controlled trial. PLoS One. 2010;5(12):6-12. doi: 10.1371/journal.pone.0015298

13. Illarioshkin SN. Adamantane derivatives in the treatment of Parkinson disease. Nervnye bolezni = Neurological Diseases. 2016;(3):14-9 (In Russ.).

14. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20:5-15. doi: 10.1111/j.1468-1331.2012.03866.x

15. DeMaagd G, Philip A. Parkinson’s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015 Oct;40(10):668-79.

16. Reichmann H, Boas J, MacMahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21-8. doi: 10.1111/j.1600-0404.2004.00363.x

17. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson’s disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditio. Eur Neurol. 2005;53(4):197-202. doi: 10.1159/000086479

18. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044- 53. doi: 10.1001/archneur.61.7.1044

19. Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol. 2012;19(2):258-64. doi: 10.1111/j.1468-1331.2011.03484.x

20. Viallet F, Pitel S, Lancrenon S, et al. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease. Curr Med Res Opin. 2013;29(1):23-31. doi: 10.1185/03007995.2012.752351

21. Wong KS, Lu CS, Shan DE, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J Neurol Sci. 2003;216(1):81-7. doi: 10.1016/S0022-510X(03)00217-X

22. Rascol O, Dubois B, Castro Caldas A, et al. Early piribedil monotherapy of parkinson’s disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006;21(12):2110-5. doi: 10.1002/mds.21122

23. Elmer LW, Juncos JL, Singer C, et al. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs. 2018;32(4):387-98. doi: 10.1007/s40263-018-0498-4

24. Parkinson Study Group. A Controlled Trial of Rasagiline in Early Parkinson Disease. The TEMPO Study. Arch Neurol. 2002 Dec;59(12):1937-43. doi: 10.1001/archneur.59.12.1937

25. Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of «off» episodes in patients with Parkinson’s disease. Curr Med Res Opin. 2007;23(4):741-50. doi: 10.1185/030079906X167697

26. Hattori N, Hasegawa K, Sato K, et al. Clinical evaluation of ropinirole controlledrelease formulation at 18–24 mg/day in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2017;40:33-9. doi: 10.1016/j.parkreldis.2017.04.005

27. Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off. J Neural Transm. 2005;112(2):221-30. doi: 10.1007/s00702-004-0184-1

28. Eggert K, Skogar Ö, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: Efficacy, safety and feasibility-an open-label, 6-week study. J Neural Transm. 2010;117(3):333-42. doi: 10.1007/s00702-009-0344-4

29. Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm. 2015;122(12):1709-14. doi: 10.1007/s00702-015-1449-6

30. Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm. 2002;109(4):489-502. doi: 10.1007/s007020200040

31. Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study. Park Relat Disord. 2013;19(11):1022-6. doi: 10.1016/j.parkreldis.2013.07.009

32. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72(6):713-20. doi: 10.1136/jnnp.72.6.713

33. Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Engl J Med. 2019;380(4):315-24. doi: 10.1056/NEJMoa1809983

34. Katunina EA, Bezdolnyi YuN, Malykhina EA, Titova NV. Experience in using levodopabenserazide. Nevrologiya, neyropsikhiatriya, psikhosomatika = Nevrology, Neiropsikhiatry, Psikhosomatiks. 2015;7(3):93-7. doi: 10.14412/2074-2711-2015-3-93-97 (In Russ.).

35. Sapronova MR, Shnajder NA. Predictors and modifiers of impulse control disorders in Parkinson’s disease. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):145- 56. doi: 10.17116/jnevro2016116111145-156 (In Russ.).

36. Biglan KM, Holloway RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187-95. doi: 10.1212/01.wnl.0000265593.34438.00

37. Bogdanov RR, Bogdanov AR, Kotov SV. Early Parkinson's disease: approaches to patient management. = 2012;73(5):15-21 (In Russ.).

38. Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson Disease (EASE LID Study): A randomized clinical trial. JAMA Neurol. 2017;74(8):941-9. doi: 10.1001/jamaneurol.2017.0943

For citation:

Tappakhov A.A., Popova T.E., Vasilev A.I., Govorova T.G., Khabarova Yu.I., Timofeeva K.A., Schnaider N.A. Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):75-81. (In Russ.)

Views: 105

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)